Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Screening for lung cancer.
Kawahara M. Kawahara M. Curr Opin Oncol. 2004 Mar;16(2):141-5. doi: 10.1097/00001622-200403000-00010. Curr Opin Oncol. 2004. PMID: 15075906 Review.
Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812).
Atagi S, Kawahara M, Tamura T, Noda K, Watanabe K, Yokoyama A, Sugiura T, Senba H, Ishikura S, Ikeda H, Ishizuka N, Saijo N; Japan Clinical Oncology Group (JCOG9812). Atagi S, et al. Among authors: kawahara m. Jpn J Clin Oncol. 2005 Apr;35(4):195-201. doi: 10.1093/jjco/hyi060. Jpn J Clin Oncol. 2005. PMID: 15845568 Clinical Trial.
Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH. Kawaguchi T, et al. Among authors: kawahara m. J Thorac Oncol. 2010 May;5(5):620-30. doi: 10.1097/JTO.0b013e3181d2dcd9. J Thorac Oncol. 2010. PMID: 20354456 Free article.
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K, Mio T, Kawahara M, Yoshioka H, Yanagihara K, Daimon T, Furuse K. Okishio K, et al. Among authors: kawahara m. Jpn J Clin Oncol. 2012 May;42(5):387-93. doi: 10.1093/jjco/hys028. Epub 2012 Mar 19. Jpn J Clin Oncol. 2012. PMID: 22430871 Clinical Trial.
920 results